Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
78.64
+0.73 (+0.93%)
Streaming Delayed Price
Updated: 3:37 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
June 10, 2024
From
AstraZeneca
Via
Business Wire
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...
Via
Talk Markets
The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now
June 07, 2024
Discover three of the best must-own stocks, showcasing resilient performance, strategic growth initiatives and consistent dividend payouts.
Via
InvestorPlace
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
June 06, 2024
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside
Via
InvestorPlace
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
June 04, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
May 22, 2024
Via
Benzinga
Large Cap BIopharmaceuticals Overview
June 03, 2024
As a defensive play healthcare is weighted at about 12% of the S&P 500.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
June 03, 2024
There's probably a big enough pie here for everyone to get a slice.
Via
The Motley Fool
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
June 02, 2024
From
AstraZeneca
Via
Business Wire
Stocks Seeing Relentless Buying Pressure; Bonds Are Not
June 02, 2024
Relentless buying pressure, to the degree that we saw in Q4 last year, is evidence of strong underlying demand for stocks. Meanwhile, after a 40-year drawdown, the 50-week rate of change for US 30-year...
Via
Talk Markets
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
June 02, 2024
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
June 02, 2024
From
AstraZeneca
Via
Business Wire
3 No-Brainer Stocks to Buy in June
June 02, 2024
Now is the time to invest in these great stocks.
Via
The Motley Fool
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
May 30, 2024
AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
May 29, 2024
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.
Via
Benzinga
Exposures
Product Safety
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
May 29, 2024
Both businesses have road maps for the future, but one is better.
Via
The Motley Fool
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
May 29, 2024
Its new strategic roadmap aims to catapult the company forward.
Via
The Motley Fool
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.
Via
Benzinga
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
May 27, 2024
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.
Via
Benzinga
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
May 27, 2024
From
AstraZeneca
Via
Business Wire
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
May 25, 2024
Via
Talk Markets
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies
May 23, 2024
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
May 23, 2024
From
AstraZeneca
Via
Business Wire
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
May 23, 2024
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later...
Via
Benzinga
The RBNZ Maintained Its Hawkish Bias, Leaving The Interest Rate At 5.5%
May 22, 2024
The Reserve Bank of New Zealand kept the official cash rate at 5.5% during its May 2024 policy meeting, extending the rate pause for the 7th straight time and confirming market expectations.
Via
Talk Markets
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
May 22, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion
May 21, 2024
AstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding oncology, biopharmaceuticals, rare disease portfolios, and launching 20 new...
Via
Benzinga
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
May 21, 2024
From
AstraZeneca
Via
Business Wire
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.